Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney D Vickery

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Pharmaceutical and Biomedical Analysis|August 2, 2002
Solid-state carbon NMR characterization of the polymorphs of roxifibanRodney D Vickery, Gregory A Nemeth, Michael B Maurin
Journal of Pharmaceutical and Biomedical Analysis|October 12, 2010
Thermal decomposition of matrix metalloproteinase inhibitors: evidence of solid state dimerizationShelley R Rabel Riley, Rodney D Vickery, Gregory A Nemeth, et al.
Journal of Pharmaceutical Sciences|November 16, 2002
Polymorphism of roxifibanMichael B Maurin, Rodney D Vickery, Shelley R Rabel, et al.
Journal of Medicinal Chemistry|August 8, 2014
Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritisJoseph B Santella, Daniel S Gardner, John V Duncia, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Pharmaceutical and Biomedical Analysis|August 2, 2002
Solid-state carbon NMR characterization of the polymorphs of roxifibanRodney D Vickery, Gregory A Nemeth, Michael B Maurin
Journal of Pharmaceutical and Biomedical Analysis|October 12, 2010
Thermal decomposition of matrix metalloproteinase inhibitors: evidence of solid state dimerizationShelley R Rabel Riley, Rodney D Vickery, Gregory A Nemeth, et al.
Journal of Pharmaceutical Sciences|November 16, 2002
Polymorphism of roxifibanMichael B Maurin, Rodney D Vickery, Shelley R Rabel, et al.
Journal of Medicinal Chemistry|August 8, 2014
Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritisJoseph B Santella, Daniel S Gardner, John V Duncia, et al.
Pageof 1